Domantis extends life of protein therapeutics
15 December, 2004 by Graeme O'NeillAlbudAbs - the latest invention of Cambridge (UK) antibody-therapeutics developer Domantis, a 36-per cent owned ally of Sydney biotech Peptech (ASX:PTD)- were yesterday launched on the market, with the promise that they can extend the half-life of protein therapeutics.
Report recommends research funding boost
10 December, 2004 by Renate KrelleA new government review has reported that investment in health and medical research delivered excellent returns and benefits to the community, and has recommended that overall Commonwealth government investment be increased to AUD$1.8 billion by 2008/9.
Meditech pursues psoriasis therapy
08 December, 2004 by Graeme O'NeillMelbourne biotech Meditech Research (ASX:MTR) has signed a collaborative research agreement with Griffith University's Institute for Glycomics to develop novel carbohydrate-based topical drugs for inflammatory skin diseases, including psoriasis.
Select Vaccines and Diagnostics CRC aim for better assays
08 December, 2004 by Melissa TrudingerSelect Vaccines (ASX: SLT) will collaborate with the CRC for Diagnostics (CDx) to develop a diagnostic assay for Epstein-Barr virus (EBV), using Select's adhesive peptide technology and the CDx's synthetic EBV peptides.
In brief: Genmab; Savient; Roche; GSK; Merck
08 December, 2004 by Staff WritersDenmark's Genmab has announced its treatment against cancer of the lymphatic system, HuMax-CD20, had shown positive results in Phase I/II studies.
Biotechs lining up to list
07 December, 2004 by Melissa TrudingerFour companies are poised to float on the Australian Stock Exchange in December and January, with at least another two companies waiting in the wings.
Cryptome to collaborate with IMB
07 December, 2004 by Melissa TrudingerCryptome (ASX: CRP) has signed a memorandum of understanding with the Institute of Molecular Bioscience (IMB) to collaborate on the identification of cardiovascular therapeutics.
QUT find may lead to schizophrenia prescription revamp
06 December, 2004 by Graeme O'NeillQueensland researchers have made a discovery that could transform the way psychiatrists prescribe anti-psychotic drugs for schizophrenia -- and possibly, for other neuropsychiatric disorders, including depression.
Regulatory: P&G, GeoPharma, Ilex, Inex
02 December, 2004 by Staff WritersThe FDA has said it is unclear whether a testosterone patch for boosting sexual desire in women, being developed by Proctor & Gamble, produced meaningful benefit or was safe over the long term. Reviewers were set to ask an advisory panel if more safety studies are needed before approval of the patch, called Intrinsa, which is being developed with Watson Pharmaceuticals.
Colman the Mayne man for 2004
29 November, 2004 by Graeme O'NeillThe awards keep coming for X-ray crystallographer Prof Peter Colman, whose 3D elucidation of the influenza virus's neuraminidase enzyme in the 1980s helped build a firewall against the most dangerous virus on the planet.
Cytopia drug shepherded into Cancer Research UK program
23 November, 2004 by Graeme O'NeillMelbourne drug-discovery biotech Cytopia has made it onto the dance card of the world's largest volunteer-supported cancer research organisation, Cancer Research UK after the UK agency agreed to take Cytopia's promising anti-cancer drug CYT997 into its clinical trial program.
WEHI, Iliad to collaborate on MS project
19 November, 2004 by Melissa TrudingerMelbourne drug development company Iliad Chemicals will collaborate with scientists at the Walter and Eliza Hall Institute (WEHI) on the development of a new class of compounds with the potential to treat multiple sclerosis.
Therapeutic promise in prize winner's work
18 November, 2004 by Susan WilliamsonLevon Khachigian, an associate professor at the University of NSW, has been awarded the 2004 Australasian Science prize for his team's work on developing potential therapeutics for vascular diseases, such as artherosclerosis, and cancer.
Molecule may be key to spinal cord regeneration
18 November, 2004 by Melissa TrudingerResearchers at the Queensland Brain Institute and the University of Melbourne have identified a molecule which they believe may play a crucial role in preventing spinal cord regeneration.
Avexa in HIV therapy partnership
15 November, 2004 by Graeme O'NeillInfectious disease drug-developer Avexa (ASX:AVX) is to work with researchers at the University of Leuven's Rega Institute in Belgium to develop a new HIV/AIDS therapy that will block the virus' integrase enzyme.
